Nyrada, Inc. · ASX:NYR
Nyrada — Corporate Update (April 2020)
25 slides from Nyrada's corporate update, Apr 30, 2020
Slide 1: Nyrada Preclinical Program & Corporate Update Presentation
30 April 2020 Sydney, Australia For personal use only Nyrada Preclinical Program & Corporate Update Presentation Sydney, 30 April 2020: Nyrada, Inc (ASX: NYR) provides to shareholders and the market the slide presentation for today’s global virtual investor event. CEO, James Bonnar and Non-Executive
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: Improving Lives, Offering Hope
For personal use only Improving Lives, Offering Hope Developing New Therapies for Cardiovascular & Neurological Disorders Nyrada Virtual Investor Event April 30, 2020 ASX:NYR 1
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not Although the Company believes that the expectations reflected in the forward looking be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 5: Presenters
Presenters For personal use only Mr John Moore Mr James Bonnar Non-Executive Chairman Chief Executive Officer 3
Slide 6: Nyrada Summary
Nyrada Summary For personal use only Diverse product portfolio with significant therapeutic and Newly listed commercial potential, with near term milestones. drug discoverer and early stage Cholesterol lowering (PCSK9 inhibitors) program to help up to 70% of patients taking statin drugs, currently a
Slide 7: Board of Directors
Board of Directors For personal use only Mr John Moore Dr Graham Kelly Christopher Cox Mr Peter Marks Mr Marcus Frampton Dr Rüdiger Weseloh Non-Executive Non-Executive Non- Executive Non- Executive Non- Executive Non- Executive Chairman Director Director Director Director Director Nyrada operates un
Slide 8: Strategy & Business Model
Strategy & Business Model For personal use only Innovative Treatments Clinical Need Market Potential Commercial Focus Discovery / Early Phase Diverse Pipeline Cardiovascular Neurology 6
Slide 9: Cholesterol and Cardiovascular Disease
Cholesterol and Cardiovascular Disease For personal use only 1 in 4 Deaths attributed to Cardiovascular Disease • Tobacco use • High blood pressure • High cholesterol Benjamin EJ et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019 7
Slide 10: High Cholesterol: The Problem
High Cholesterol: The Problem For personal use only Narrowing artery potentially leading to heart disease or stroke Artery Atherosclerotic plaque (LDL-cholesterol accumulation) 8
Slide 11: Cholesterol Problem (US)
Cholesterol Problem (US) For personal use only 62.6 million 19.4 million 27.4 million Unable to achieve US adults with elevated Total US adults with LDL-C target despite LDL-C are taking a statin elevated LDL-C taking statin therapy Wong ND et al. Prevalence of the American College of Cardiology/Ame
Slide 12: Cholesterol-Lowering Treatment Options
Cholesterol-Lowering Treatment Options For personal use only Low cost generics available Launched March 2020 Effective, combined with statin US$16 per 100 pills US$3,600 per year Developed for use with a statin Suboptimal efficacy standalone Expensive US$5,800 per year Inconvenient (2-4 weekly injec
Slide 13: Nyrada Cholesterol-Lowering Solution
Nyrada Cholesterol-Lowering Solution For personal use only Blocks action of PCSK9 on cholesterol receptor Statins increase PCSK9 levels Small molecule PCSK9 inhibitor High PCSK9 = overcomes longstanding challenge high LDL cholesterol of an oral PCSK9 treatment 11
Slide 14: What is Unique?
What is Unique? For personal use only Single pill Convenient Cost- treatment for patient effective 12
Slide 15: Cholesterol Drug Market (Non-Statin)
Cholesterol Drug Market (Non-Statin) For personal use only Injectable Evolocumab (Repatha) Marketed Amgen PCSK9 inhibitor Monoclonal Alirocumab (Praluent) Marketed Sanofi/Regeneron PCSK9 inhibitor Monoclonal Inclisiran Phase III The Medicines Company / Novartis PCSK9 siRNA siRNA Evinacumab Phase III
Slide 16: Brain Injury Problem
Brain Injury Problem For personal use only Each year in the US: Neurology / physical rehabilitation only existing - High mortality - 2.8 million people sustain therapies - Severe life-long disability a traumatic brain injury (TBI) - One drug class for stroke - High ongoing healthcare (Suitable for l
Slide 17: Potential Effects of Brain Injury
Potential Effects of Brain Injury For personal use only May lead to short- or long-term issues affecting: Cognitive Function - attention and memory Motor function - extremity weakness, impaired coordination and balance Sensation - hearing, vision, impaired perception and touch Behaviour - emotional
Slide 18: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution For personal use only Treatment for secondary brain injury following Stroke or TBI - Prevent cell death - Attenuate damaged brain volume - Improve survivability, limit disability, improve quality of life Primary Secondary Disability Injury Injury Level Hours Days Weeks M
Slide 19: Brain Injury Drug Market
Brain Injury Drug Market For personal use only Hospital admissions each year (US) Patients who present within 12 hour window 280,000 Traumatic Brain Injury (Moderate / Severe) 210,000 700,000 patients 650,000 Annual US market size for Stroke brain injury combined (approx.) 490,000 US$20B global seve
Slide 20: Program Status
Program Status For personal use only First-in-human studies (Phase I) Proof-of-concept Lead optimisation well established advanced - Cholesterol-lowering: late-2021 - Neuroprotection: mid-2022 18
Slide 21: Scientific Advisory Board
Scientific Advisory Board For personal use only Prof Gary Housley Prof Junichi Nabekura Prof David Burke Prof Gilles Lambert Jim Palmer MSc PhD PhD MD DSc AC PhD PhD International team of experts with vast experience in drug development 19
Slide 22: Key Metrics & News Flow
Key Metrics & News Flow For personal use only Market capitalisation H2 H1 H2 H1 $20M 2020 2021 2021 2022 (as at 29 April 2020) Share price Lead product candidate selection for $0.18 cholesterol program: (as at 29 April 2020) Lead product candidate selection for CDIs free float 76,072,869 neuroprotec
Slide 23: Summary
Summary For personal use only Diverse portfolio Large, under-served therapeutic areas Compelling proof of concept data Commercial business model Right team and well-funded to execute 21
Slide 24: Discover More & Follow Us
Discover More & Follow Us For personal use only Neuroprotection Cholesterol-Lowering Recent PCSK9i Animation Animation Publication @nyrada_inc @nyrada_inc www.nyrada.com 22
Slide 25: For personal use only
For personal use only 23